A PIM₂ analogue suppresses allergic airway disease

Jacquie L Harper; Colin M Hayman; David S Larsen; Gavin F Painter; Gurmit Singh-Gill

doi:10.1016/j.bmc.2010.11.058

A PIM₂ analogue suppresses allergic airway disease

Bioorg Med Chem. 2011 Jan 15;19(2):917-25. doi: 10.1016/j.bmc.2010.11.058. Epub 2010 Dec 2.

Authors

Jacquie L Harper¹, Colin M Hayman, David S Larsen, Gavin F Painter, Gurmit Singh-Gill

Affiliation

¹ The Malaghan Institute of Medical Research, Wellington, New Zealand.

PMID: 21215641
DOI: 10.1016/j.bmc.2010.11.058

Abstract

Two approaches for the synthesis of a phosphatidylinositol dimannoside (PIM₂) analogue 4 that mimics the suppressive activity of natural PIMs and also synthetic PIM₂ have been developed. This analogue, where the inositol core was replaced by glycerol, was tested for its ability to suppress cellular inflammation in a mouse model of allergic asthma and shown to be effective in suppressing airway eosinophilia. Suppression of all inflammatory cells monitored was observed, indicating a general blockade of cellular activity. These data indicate that the inositol core is not essential for this suppressive activity.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Intranasal
Animals
Anti-Allergic Agents / chemical synthesis
Anti-Allergic Agents / chemistry*
Anti-Allergic Agents / therapeutic use
Asthma / drug therapy*
Mice
Ovalbumin / immunology
Phosphatidylinositols / chemical synthesis
Phosphatidylinositols / chemistry*
Phosphatidylinositols / therapeutic use
Pulmonary Eosinophilia / drug therapy

Substances

Anti-Allergic Agents
Phosphatidylinositols
phosphatidylinositol dimannoside
Ovalbumin